Jazz Pharma Ireland Ltd v. Tris Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland)
  • Defendant: Tris Pharma, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01739, D.N.J., 02/20/2026
• Venue Allegations: Venue is asserted based on Defendant Tris Pharma, Inc. being a New Jersey corporation with its principal place of business in the district, conducting continuous business in the district, and having previously availed itself of the jurisdiction of the court.
• Core Dispute: Plaintiff alleges that Defendant's submission of a New Drug Application (NDA) for a generic version of Plaintiff's Xyrem® (sodium oxybate) drug product constitutes an act of infringement under the Hatch-Waxman Act, violating seven patents related to methods of administering gamma hydroxybutyrate (GHB).
• Technical Context: The technology involves pharmaceutical methods for safely co-administering GHB, a treatment for narcolepsy, with other common drugs that are known to inhibit monocarboxylate transporters (MCTs), thereby affecting GHB's efficacy and safety profile.
• Key Procedural History: The suit was initiated under the Hatch-Waxman Act following Defendant's submission of NDA No. 220138 and a Paragraph IV Certification to the FDA, alleging that Plaintiff's patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic product. Defendant provided notice of this certification to Plaintiff no earlier than January 9, 2026. The complaint notes other related litigation involving the same plaintiff and some of the same patents.

Case Timeline

Date	Event
2013-03-01	Earliest Priority Date for '400, '181, '494, and '446 Patents
2013-03-15	Earliest Priority Date for '306, '302, and '426 Patents
2014-07-08	U.S. Patent No. 8,772,306 Issues
2015-06-09	U.S. Patent No. 9,050,302 Issues
2016-11-08	U.S. Patent No. 9,486,426 Issues
2019-02-26	U.S. Patent No. 10,213,400 Issues
2020-12-15	U.S. Patent No. 10,864,181 Issues
2022-02-22	U.S. Patent No. 11,253,494 Issues
2024-05-21	U.S. Patent No. 11,986,446 Issues
2026-01-09	Earliest Date Defendant Sent Paragraph IV Notice Letter
2026-02-20	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,772,306 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters, Issued July 8, 2014

The Invention Explained

• Problem Addressed: The patent addresses the safety risks arising from drug-drug interactions with gamma-hydroxybutyrate (GHB), a treatment for narcolepsy Compl. ¶13 It notes that certain other drugs, known as monocarboxylate transporter (MCT) inhibitors, can alter the effects of GHB in the body, creating potentially unsafe conditions for the patient '306 Patent, abstract For example, the anti-seizure medication valproate can dangerously increase the effect of GHB '400 Patent, abstract
• The Patented Solution: The invention provides a method for safely administering GHB to a patient who is also taking an MCT inhibitor. The solution involves adjusting the dosage of GHB to compensate for the interaction. Specifically, when a patient is concomitantly taking valproate, the patented method calls for reducing the daily dosage of GHB by a specified percentage range to diminish the potentially additive, and thus harmful, effects '306 Patent, col. 2:30-49
• Technical Importance: This method provides a systematic approach for physicians to safely co-prescribe Xyrem® (GHB) with other necessary medications like valproate, mitigating the risk of adverse events due to otherwise unpredictable drug interactions.

Key Claims at a Glance

• The complaint does not identify specific claims but alleges infringement of "one or more" claims Compl. ¶29 Independent claim 1 is representative of the patent's core method.
• Independent Claim 1:
  • A method for reducing adverse effects caused by a combination of GHB (or a salt thereof) and divalproex sodium in a patient.
  • The method comprises administering to the patient a daily dosage amount of GHB that is about 15% to about 35% lower than the recommended daily dosage amount used in the absence of divalproex sodium.
  • The method specifies that the recommended daily dosage amount of GHB (absent divalproex sodium) is between 4.5 g and 9 g.
• The complaint reserves the right to assert infringement of other claims Compl. ¶29

U.S. Patent No. 9,050,302 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters, Issued June 9, 2015

The Invention Explained

• Problem Addressed: As with the '306 patent, this patent addresses the safety risks of co-administering GHB with MCT inhibitors like valproate, which can potentiate the effects of GHB and lead to adverse events '302 Patent, abstract '302 Patent, col. 1:17-24
• The Patented Solution: The patent claims a method of treating narcolepsy or excessive daytime sleepiness in a patient who is already taking GHB. The method involves reducing the daily dosage of GHB by at least 20% when that patient is also being concomitantly administered divalproex sodium. This reduction compensates for the potentiating effect of divalproex sodium on GHB '302 Patent, col. 2:5-18
• Technical Importance: This patented method provides physicians with a clear, quantitative guideline for dose reduction, enhancing the safety of patients with narcolepsy who require polypharmacy involving both GHB and divalproex sodium.

Key Claims at a Glance

• The complaint alleges infringement of "one or more" claims Compl. ¶38 Independent claim 1 is a representative method claim.
• Independent Claim 1:
  • A method for treating cataplexy in narcolepsy or excessive daytime sleepiness in a patient currently taking GHB.
  • The method comprises reducing the daily dosage amount of GHB administered to the patient by at least 20%.
  • This reduction is performed for a patient who is concomitantly administered divalproex sodium.
  • The method specifies that the daily dosage amount of GHB in the absence of divalproex sodium is between 4.5 g to 9 g.
• The complaint reserves the right to assert infringement of other claims Compl. ¶38

Multi-Patent Capsule: '426, '400, '181, '494, and '446 Patents

• Patent Identification: U.S. Patent Nos. 9,486,426 (issued Nov. 8, 2016); 10,213,400 (issued Feb. 26, 2019); 10,864,181 (issued Dec. 15, 2020); 11,253,494 (issued Feb. 22, 2022); and 11,986,446 (issued May 21, 2024). All are titled Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Compl. ¶¶6-10
• Technology Synopsis: These patents are part of the same family as the '306 and '302 patents and address the same technical problem: managing drug-drug interactions between GHB and MCT inhibitors. They claim methods for safely administering GHB by adjusting its dosage when co-administered with drugs like valproate (which increases GHB's effect) or diclofenac (which decreases GHB's effect), thereby maintaining a safe and effective therapeutic window '400 Patent, abstract '400 Patent, col. 2:16-62
• Asserted Claims: The complaint asserts infringement of "one or more claims" of each patent (Compl. ¶¶47; Compl. ¶56; Compl. ¶65; Compl. ¶74; Compl. ¶83).
• Accused Features: For each patent, the accused act is Tris's submission of its NDA seeking approval to market a generic oxybate product before the expiration of the patent (Compl. ¶¶47; Compl. ¶56; Compl. ¶65; Compl. ¶74; Compl. ¶83). Infringement is premised on the fact that the proposed product and its label will instruct or encourage administration in a manner covered by the patents' method claims.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Tris's Proposed Product," an oxybate product for which Defendant submitted New Drug Application (NDA) No. 220138 to the FDA Compl. ¶1 Compl. ¶24

Functionality and Market Context

The complaint alleges that Tris's Proposed Product is a version of Jazz Pharmaceuticals' Xyrem® drug product Compl. ¶1 Xyrem® is a trade name for sodium oxybate, an oral solution approved for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy Compl. ¶11 Compl. ¶13 The infringement action was triggered by Tris's filing of an NDA under Section 505(b)(2) of the FFDCA, an act which, if seeking approval to market a drug claimed in a patent before its expiration, constitutes a statutory act of infringement Compl. ¶24 Compl. ¶29 The complaint alleges that upon approval, Tris will commercially manufacture, use, and sell this product in the United States Compl. ¶25

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide specific, element-by-element infringement allegations. The infringement action is premised on 35 U.S.C. § 271(e)(2)(A), which defines the submission of an NDA seeking to market a patented drug prior to patent expiration as an act of infringement. The substantive infringement theory is that the proposed labeling for Tris's product will instruct or encourage end-users (physicians and patients) to practice the patented methods. The following tables summarize this high-level theory as it applies to representative independent claims.

U.S. Patent No. 8,772,306 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for reducing adverse effects caused by a combination of gamma-hydroxybutyrate (GHB) or a salt thereof and divalproex sodium in a patient...	Submission of NDA No. 220138 for a product whose proposed label will instruct or encourage co-administration with divalproex sodium.	¶29	col. 2:30-36
comprising: administering to the patient a daily dosage amount of GHB or salt thereof that is about 15% to about 35% lower than the recommended daily dosage amount in the absence of concomitant administration of divalproex sodium...	The proposed label will allegedly instruct a dosage adjustment that falls within the claimed percentage reduction range when the product is co-administered with divalproex sodium.	¶29	col. 2:36-42
wherein the recommended daily dosage amount of GHB or salt thereof in the absence of concomitant administration of divalproex sodium is between 4.5 g and 9 g.	The proposed product is a version of Xyrem®, whose FDA-approved labeling includes this dosage range, and Tris's product will allegedly carry a similar label.	¶1; ¶13	col. 2:43-49

U.S. Patent No. 9,050,302 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for the treatment of cataplexy in narcolepsy or excessive daytime sleepiness in narcolepsy in a patient who is currently taking gamma-hydroxybutyrate (GHB) or a salt thereof...	Submission of NDA No. 220138 for a product intended to treat narcolepsy, with a proposed label that will instruct use in patients currently taking GHB.	¶38	col. 2:5-9
comprising: reducing the daily dosage amount of GHB or salt thereof administered to the patient by at least 20%... for a patient who is concomitantly administered divalproex sodium...	The proposed label will allegedly instruct a dose reduction of at least 20% for patients who are also taking divalproex sodium.	¶38	col. 2:9-14
wherein the daily dosage amount of GHB or salt thereof in the absence of concomitant administration of divalproex sodium is between 4.5 g to 9 g.	The proposed product is a version of Xyrem®, whose FDA-approved labeling includes this dosage range, and Tris's product will allegedly carry a similar label.	¶1; ¶13	col. 2:15-18

Identified Points of Contention

• Scope Questions: A central dispute will likely involve claim construction. For instance, does the term "about 15% to about 35% lower" in the '306 patent, or "at least 20%" in the '302 patent, read on the specific instructions, if any, in the proposed label of Tris's product? The interpretation of "about" and the precision of the dosage reduction instructions will be critical.
• Factual & Legal Questions: A primary question for the court will be whether the instructions and recommendations in the proposed label for Tris's product actually induce infringement of the patented methods. This analysis will depend on the final language of the FDA-approved label. Additionally, Tris's Paragraph IV certification raises the question of patent validity and/or enforceability, which will be a key area of dispute Compl. ¶26

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a definitive analysis of claim construction disputes. However, based on the technology and the nature of the method claims, certain terms will likely be central.

• The Term: "reducing the daily dosage amount ... by about 15% to about 35% lower" '306 Patent, claim 1

• Context and Importance: This phrase is the central, quantitative step of the claimed method. The infringement analysis will turn on whether the proposed label for Tris's product instructs a dose reduction that falls within this range. Practitioners may focus on this term because the scope of "about" will determine whether a dose reduction instruction that is not literally 15-35% (e.g., 14% or 36%) could still be found to infringe.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification's repeated use of "about" in describing various percentage ranges may support a construction that is not rigidly fixed to the exact numbers, but encompasses values reasonably close to the stated range '306 Patent, col. 2:49-65
  • Evidence for a Narrower Interpretation: The patent discloses specific clinical study results and embodiments '306 Patent, Example 2 A party might argue that the term "about" should be limited to the range of variability observed in those specific examples, potentially narrowing the claim's scope.

• The Term: "concomitantly administered" '302 Patent, claim 1

• Context and Importance: The temporal relationship between the administration of GHB and divalproex sodium is fundamental to the claimed method. The definition will determine what constitutes a "concomitant" regimen. Practitioners may focus on this term to argue whether infringement requires the drugs to be taken at the same time, on the same day, or simply as part of an overlapping treatment period.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification describes clinical study protocols where divalproex was dosed for a number of days to reach steady-state before GHB was introduced, suggesting "concomitant" refers to a state where both drugs are therapeutically active in the patient, not necessarily simultaneous ingestion '400 Patent, col. 21:50-60
  • Evidence for a Narrower Interpretation: A party could argue that the plain meaning implies administration at or near the same time. The patent's detailed description of drug interaction studies, where doses are given on specific study days, might be used to argue for a narrower timeframe, though this is less likely given the pharmacological context '400 Patent, col. 21:1-22:24

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Tris will induce infringement by "intentionally encourag[ing] acts of direct infringement" through its product, presumably via its labeling and instructions Compl. ¶32 Compl. ¶41 It also alleges contributory infringement, stating that Tris's product is "especially adapted for a use that infringes" and has "no substantial non-infringing use" Compl. ¶33 Compl. ¶42
• Willful Infringement: The complaint does not use the term "willful infringement." However, it alleges that each count represents an "exceptional" case and requests attorneys' fees under 35 U.S.C. § 285 Compl. ¶36 Compl. ¶45 The basis for this is Tris's alleged knowledge of the patents, as evidenced by its Paragraph IV certification and notice letter Compl. ¶26 Compl. ¶27

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of label-based inducement: will the final, FDA-approved label for Defendant's proposed generic product be found to affirmatively instruct or encourage physicians to perform the specific, quantitative dose-adjustment steps as required by the asserted method claims, thereby inducing infringement?
• A second key question will be one of patent validity: can the asserted claims, which are directed to specific percentage-based dosage adjustments for a known drug interaction, withstand Defendant's inevitable challenges under 35 U.S.C. §§ 103 (obviousness) and 112 (written description and enablement), as foreshadowed by the Paragraph IV certification?
• A third central question will be one of claim scope: how broadly will the court construe quantitative terms such as "about 15% to about 35% lower" and "at least 20%," particularly the word "about"? The outcome of this construction will be dispositive for the infringement analysis.